)
)
)
Carna Biosciences, Inc.
Carna Biosciences is a clinical-stage company focused on discovering and developing small molecule drugs targeting oncology and autoimmune diseases. Carna’s pipeline includes a non-covalent BTK inhibitor for allergic diseases, a potential first-in-class STING antagonist for immune disorders, a next-generation wild-type & pan-mutant BTK inhibitor for CLL, and a potential first-in-class CDC7 inhibitor for blood cancers.
Carna is actively seeking strategic partners to accelerate the clinical development of our pipeline.
(1) Sofnobrutinib (Ph 2-ready): non-covalent BTK inhibitor for allergic diseases
(2) AS-5908 (preclinical): potential first-in-class oral STING antagonist for immune disorders
(3) Docirbrutinib (Ph 1b): next-generation wild & pan-mutant BTK inhibitor for CLL (AS-1763)
(4) Monzosertib (Ph 1): potential first-in-class CDC7 inhibitor for blood cancers
Address
KobeJapan
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)